<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00531986</url>
  </required_header>
  <id_info>
    <org_study_id>SHCS-Projekt Nr.: 490</org_study_id>
    <secondary_id>SHCS 490</secondary_id>
    <nct_id>NCT00531986</nct_id>
  </id_info>
  <brief_title>HIV - Monotherapy in Switzerland (MOST-ch)</brief_title>
  <acronym>MOST</acronym>
  <official_title>HIV- Monotherapy in Switzerland (MOST- ch)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cantonal Hospital of St. Gallen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss National Science Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swiss HIV Cohort Study</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cantonal Hospital of St. Gallen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators plan to conduct a two arm study, to compare failure rates in the central&#xD;
      nervous system (CNS) and genital compartment in virologically fully suppressed patients&#xD;
      continuing a highly active antiretroviral therapy (HAART) versus patients switching to&#xD;
      ritonavir boosted lopinavir (Kaletra®) HIV-monotherapy. The study is composed of two phases&#xD;
      of 48 weeks duration.&#xD;
&#xD;
      In addition, neuropsychological tests (Color trial test A 1 and 2; Grooved pegboard; EWIA&#xD;
      Digit Symbol form) and evaluation of side effects will be performed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the first phase (phase A), ritonavir-boosted lopinavir (Kaletra®) will be compared with&#xD;
      continued HAART. In the second year (phase B) patients on conventional HAART are also offered&#xD;
      LPV/r monotherapy to extend the longterm experience of this new strategy.&#xD;
&#xD;
      Only patients willing to give a genital secretion and a spinal fluid sample will be included.&#xD;
      All patients must be on a fully suppressive HAART with at least 2 consecutive values of&#xD;
      HIV-RNA at the screening visit . After performance of lumbar puncture at baseline, patients&#xD;
      will be randomized to continued HAART or LPV/r monotherapy. During the first year of&#xD;
      randomized treatment patients will be followed at week 6/ 12 /18 /24 /32 /40 and 48. Lumbar&#xD;
      puncture and genital secretion sampling will be repeated at week 48.&#xD;
&#xD;
      Follow up during the second phase (B: W48-96) of the study will be identical to phase A&#xD;
      including genital and spinal sampling at week 96. After study termination at week 96,&#xD;
      patients may opt to continue monotherapy if results of HIV-RNA in blood and CSF support this&#xD;
      decision.&#xD;
&#xD;
      The primary endpoint of the study will be treatment failure in the compartment (CSF and / or&#xD;
      genital tract). Since the variability of HIV-RNA determination in CSF and genital secretions&#xD;
      is not very well known, a one log increase above the baseline value will be considered as&#xD;
      treatment failure in the respective compartment. Only patients who had a complete viral&#xD;
      suppression in blood will be considered for compartment evaluation. Patients treated in the&#xD;
      monotherapy arm with a CSF HIV-RNA value at week 48 more than 1.0 log10 cp/ml above baseline&#xD;
      (= compartment failure) will be switched to a conventional combination treatment. HIV-RNA&#xD;
      testing in the genital samples will be performed batchwise at the end of the study.&#xD;
&#xD;
      In addition, patients with a blood treatment failure (two consecutive HIV-RNA detections &gt;&#xD;
      400cp/ml) will be considered as full treatment failures and switched to a rescue regimen at&#xD;
      the discretion of the treating physician. For the analysis, these patients will be considered&#xD;
      as systemic treatment failure and will not be entered in the analysis of compartmentalized&#xD;
      treatment failure. If the rescue strategy was only intensification of adherence and results&#xD;
      in full blood viral load re-suppression, the patient will still be maintained in the study&#xD;
      and compartment evaluations can be performed at w48 and/or 96, respectively.&#xD;
&#xD;
      The secondary aim of the study is the definition of prognostic markers for compartment&#xD;
      failures. Potential risk factors associated with mono-maintenance failure are HIV-DNA load at&#xD;
      time of treatment simplification, HIV-RNA at the time of first treatment initiation, duration&#xD;
      of HIV-RNA suppression before simplification, history of HIV-RNA blips, presence of&#xD;
      detectable HIV-RNA in spinal fluid at the time of treatment simplification, changes of level&#xD;
      of c-reactive protein (high sensitive methodology, hsCRP) from baseline as a marker of&#xD;
      immune-activation during the maintenance therapy.&#xD;
&#xD;
      If funding allows, we will test for the presence of resistant viruses and compare the&#xD;
      presence of genetic polymorphism at baseline. We will also measure parameters of&#xD;
      immunoactivation (hsCRP, CD8+, CD38+).&#xD;
&#xD;
      The study is financed by the Swiss National Science Foundation and the Swiss HIV Cohort&#xD;
      Study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unexpectedely high rates of treatment-failure&#xD;
  </why_stopped>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Failure in CNS</measure>
    <time_frame>Week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Predictors of failure</measure>
    <time_frame>week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ritonavir-boosted lopinavir (Kaletra®) will be used as monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continued ART</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuation Therapy, conventional triple HAART</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir-Monotherapy</intervention_name>
    <description>Patients on triple HAART will be switched to LPV/r-monotherapy</description>
    <arm_group_label>Monotherapy</arm_group_label>
    <other_name>Kaletra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HAART</intervention_name>
    <description>Patients will continued their current HAART</description>
    <arm_group_label>Continued ART</arm_group_label>
    <other_name>Any ART</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years.&#xD;
&#xD;
          -  HIV seropositive.&#xD;
&#xD;
          -  HAART (&gt; 6 months) with at least 3 months successfully suppressed HIV- RNA (two most&#xD;
             recent RNA measurements &lt; 50 cp/ml). HAART is defined as either:&#xD;
&#xD;
               -  1 PI plus 2 NRTIs,&#xD;
&#xD;
               -  1 NNRTI plus 2 NRTIs, or&#xD;
&#xD;
               -  3 NRTIs.&#xD;
&#xD;
          -  HIV-RNA in plasma &lt; 50 cp/ml at screening.&#xD;
&#xD;
          -  Stable antiretroviral therapy (unchanged drug combination) during the last four weeks.&#xD;
&#xD;
          -  If not currently on a LPV/ r based therapy, willing to switch to LPV/ r bid therapy in&#xD;
             case patient is randomized to the monotherapy arm&#xD;
&#xD;
          -  Signed written informed consent.&#xD;
&#xD;
          -  Highly motivated patients able to understand the investigational nature of this open&#xD;
             observational study and willing to participate in additional procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other investigational substance or substances active against HIV.&#xD;
&#xD;
          -  Previous history of adverse events with the drugs under investigation.&#xD;
&#xD;
          -  Previous history of any virological treatment failure (does not include deliberate&#xD;
             treatment interruption) or documented resistance against the drugs under investigation&#xD;
             (LPV/r).&#xD;
&#xD;
          -  Patient who has no effective alternative treatment options in case the study treatment&#xD;
             fails (according to the physician's judgment).&#xD;
&#xD;
          -  Pregnancy (negative pregnancy test for women of childbearing potential at screening).&#xD;
&#xD;
          -  Active AIDS-defining disease necessitating antibiotic or chemotherapy at the time of&#xD;
             screening.&#xD;
&#xD;
          -  Chronic hepatitis B.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pietro Vernazza, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Swiss HIV Cohort Study</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Flepp</name>
      <address>
        <city>Zürich</city>
        <state>Bellariastrasse 38</state>
        <zip>8038</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furrer</name>
      <address>
        <city>Bern</city>
        <state>INF KP PKT 2B Freiburgstr.</state>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuesch</name>
      <address>
        <city>Basel</city>
        <state>Petersgraben 4</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cavassini</name>
      <address>
        <city>Lausanne</city>
        <state>Rue Du Bugnon 21</state>
        <zip>1005</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opravil</name>
      <address>
        <city>Zürich</city>
        <state>Rämistrasse 100</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hirschel</name>
      <address>
        <city>Geneva</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.infekt.ch</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>September 18, 2007</study_first_submitted>
  <study_first_submitted_qc>September 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2007</study_first_posted>
  <last_update_submitted>July 16, 2018</last_update_submitted>
  <last_update_submitted_qc>July 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cantonal Hospital of St. Gallen</investigator_affiliation>
    <investigator_full_name>pietro vernazza</investigator_full_name>
    <investigator_title>Director Division Infectious Diseases</investigator_title>
  </responsible_party>
  <keyword>Monotherapy</keyword>
  <keyword>Neuropsychological tests</keyword>
  <keyword>HIV viral load in ZNS</keyword>
  <keyword>HIV viral load in genital</keyword>
  <keyword>Lumbar puncture and HIV viral load in ZNS</keyword>
  <keyword>Monotherapy and compartment failure (ZNS and genital)</keyword>
  <keyword>ZNS viral load under monotherapy</keyword>
  <keyword>Genital viral load under monotherapy</keyword>
  <keyword>Neuropsychological tests (HIV Dementia)</keyword>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lopinavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

